Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
Launched by MASSACHUSETTS GENERAL HOSPITAL · Dec 13, 2012
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- Must satisfy A and B and C below:
- • A. Women aged 45+
- • B. Postmenopausal
- • C. Osteoporotic with high risk of fracture
- Exclusion Criteria:
- • History of significant hepatic, renal, cardiovascular, malignant disease, or conditions with impaired immune system
- • Current alcohol or substance abuse
- • Major psychiatric disorders
- • Abnormal calcium level, elevated PTH, vitamin D deficiency, or anemia
- • Known congenital or acquired bone disease other than osteoporosis
- • Current use or past use in the past 12 months of oral bisphosphonates
- • Current use or use in the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin
- • Use of oral or parenteral glucocorticoids for more than 14 days in the past 6 months
- • Any current or previous use of strontium or intravenous bisphosphonates
- • Sensitivity to cell-derived drug products or teriparatide
- • Extensive dental work involving dental extraction or dental implant within the past 2 months or in the upcoming 2 months
- • Inability to sit upright for 30 minutes
- • Esophageal abnormalities
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials